Current Report Filing (8-k)

Date : 08/07/2017 @ 7:01AM
Source : Edgar (US Regulatory)
Stock : Zynerba Pharmaceuticals, Inc. (MM) (ZYNE)
Quote : 6.36  0.0 (0.00%) @ 7:23AM

Current Report Filing (8-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8–K

 


 

CURRENT REPORT

Pursuant to Section 13 OR 15 (d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): August 7, 2017

 


 

ZYNERBA PHARMACEUTICALS, INC.

(Exact Name of Issuer as Specified in Charter)

 


 

Delaware

 

001-37526

 

26-0389433

(State or Other Jurisdiction of
Incorporation or Organization)

 

(Commission
File Number)

 

(I.R.S. Employer
Identification No.)

 

80 W. Lancaster Avenue, Suite 300

Devon, PA 19333

(Address of Principal Executive Offices)

 

(484) 581-7505

(Registrant’s Telephone Number, Including Area Code)

 


 

Check the appropriate box below if the Form 8–K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o       Soliciting material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12)

 

o       Pre–commencement communications pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b))

 

o       Pre–commencement communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 



 

Item 8.01      Other Events

 

On August 7, 2017, Zynerba Pharmaceuticals, Inc. issued a press release announcing top-line results from its double-blind placebo controlled Phase 2 STAR 1 ( S ynthetic T ransdermal C a nnabidiol for the T r eatment of Epilepsy) clinical trial evaluating ZYN002 (cannabidiol gel) in adult epilepsy patients with focal seizures.  A copy of this press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

Item 9.01  Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
No.

 

Document

 

 

 

99.1

 

Press Release, dated August 7, 2017.

 

2



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 7, 2017

 

 

 

ZYNERBA PHARMACEUTICALS, INC.

 

 

 

 

 

 

 

By:

/s/ Suzanne Hanlon

 

 

Name: Suzanne Hanlon

 

 

Title: Secretary, General Counsel and
Vice President, Human Resources

 

3



 

EXHIBIT INDEX

 

Exhibit
No.

 

Document

 

 

 

99.1

 

Press Release, dated August 7, 2017.

 

4


ZYNERBA PHARMACEUTICALS, INC. (NASDAQ:ZYNE)
Historical Stock Chart

1 Year : From Aug 2016 to Aug 2017

Click Here for more ZYNERBA PHARMACEUTICALS, INC. Charts.

ZYNERBA PHARMACEUTICALS, INC. (NASDAQ:ZYNE)
Intraday Stock Chart

Today : Thursday 17 August 2017

Click Here for more ZYNERBA PHARMACEUTICALS, INC. Charts.

Latest ZYNE Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.